22nd Century Group (Nasdaq: XXII) has acquired GVB Biopharma. Read the press release here
Date | Form | Description | XBRL | Pages | |
---|---|---|---|---|---|
05/28/21 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
![]() |
6 | |
05/28/21 | S-8 POS | Post-effective amendment to a S-8 registration statement |
![]() |
6 | |
05/28/21 | S-8 POS | Post-effective amendment to a S-8 registration statement |
![]() |
6 | |
05/28/21 | S-8 POS | Post-effective amendment to a S-8 registration statement |
![]() |
6 | |
05/28/21 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
![]() |
3 | |
05/21/21 | 8-K | Current report filing |
![]() |
![]() ![]() ![]() |
11 |
05/12/21 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
![]() |
2 | |
05/06/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
37 |
05/06/21 | 8-K | Current report filing |
![]() |
![]() ![]() ![]() |
30 |
05/04/21 | 8-K | Current report filing |
![]() |
![]() ![]() ![]() |
4 |